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Infections with rapidly growing mycobacteria: 
report of 20 cases 
Somnuek Sungkanuparph, (i) Boonmee Sathapatayavongs (i) and Roongnapa Pracharktam@) 
Objectives: A series of cases infected with rapidly growing mycobacteria was studied to determine the spectrum of 
disease, antimicrobial susceptibility, treatment, and outcome. 
Methods: The cases identified as infections with rapidly growing mycobacteria in Ramathibodi Hospital from January 
1993 to December 1999 were retrospectively studied. 
Results: Most of the cases had no underlying disease. Only two cases were HIV-infected patients. The presenting 
clinical features were lymphadenitis (seven cases), skin and/or subcutaneous abscess (seven cases), localized eye 
infection (four cases), pulmonary infection (one case), and chronic otitis media (one case). Four of seven cases with 
lymphadenitis had Sweet’s syndrome, and one had psoriasis as an associated skin manifestation. Anemia was present 
in five cases, and improved with treatment of the primary disease. The organisms were Mycobacterium 
chelonadabscessus group (17 cases) and Mycobacterium fortuitum group (three cases). Susceptibility patterns of the 
organisms showed susceptibility to amikacin, netilmicin, and imipenem. M. fortuitum group was susceptible to more 
antibiotics than M. cheZonae/abscessus group. The clinical responses corresponded to the antimicrobial susceptibility. 
Combinations of two or more drugs were used for the medical treatment. Surgical resection was performed where 
possible, to reduce the load of the organism, especially in cases with very resistant organisms. 
Conclusions: Infections with rapidly growing mycobacteria can occur in apparently normal hosts. The clinical 
syndrome is variable.The pathology is nonspecific. Clinical responses varied, but seemed to correlate with the in vitro 
susceptibility result. More studies are needed to enable us to deal with this infection effectively. 
Int J Infect Dis 2003; 7: 198-205 
INTRODUCTION 
Mycobacterium chelonae, Mycobacterium abscessus and 
Mycobacterium fortuitum group are the major pathogens 
among the rapidly growing mycobacteria. Infections 
caused by these organisms are not uncommon, and the 
incidence is increasing. The clinical syndrome is 
variab1e.l The diseases can involve many tissues and 
organ systems, and include skin and soft tissue 
infectionsz4 lymphadenitis5 pulmonary infections,6-8 
arthritis9 keratitis,lO-I2 endophthalmitis,r3 otitis media 
and mastoiditis,14,15 catheter-related infection,16,17 peri- 
prosthetic infectionI and disseminated infection.19,20 
Most of the patients are immunosuppressed or have 
antecedent chronic illness.20 The course of disease is 
highly variable. l-z0 Treatment is difficult, because the 
organisms do not respond to traditional antituberculous 
agents and most antibiotics, and relapse is common. 
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A controlled trial defining the optimal treatment 
regimen is not available, due to limited numbers of 
patients, and variations in the clinical syndrome and 
clinical course. Our report of 20 cases may offer data 
that will be of use in both treatment and research in the 
future. 
MATERIALS AND METHODS 
Clinical aspects 
Records of the cases infected with M. chelonae/abscessus 
group and M. fortuitum group in our Division of 
Infectious Diseases and Microbiology Laboratory from 
January 1993 to December 1999 were retrospectively 
reviewed. Only the cases that fulfilled the diagnostic 
criteria for nontuberculous mycobacterial infection as 
described by the American Thoracic Society21 were 
included. The medical records of the cases were 
reviewed for demographic data and information regard- 
ing underlying diseases, clinical features, antimicrobial 
susceptibility, pathology of the tissues, treatment, and 
outcome. 
The definition of organ involvement required 
positive culture from the tissue or sterile specimen, or 
suggestive histologic findings of second organ involve- 
ment. The outcome of treatment was defined as good, 
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fair, or poor, depending on general condition, body 
weight, resolution of presenting symptoms and physical 
findings, negative culture, and absence of clinical relapse. 
Microbiological aspects 
Acid-fast stain of the clinical specimens was done by the 
carbol fuschin method (Kinyoun stain). Clinical 
specimens from various sites were cultured on routine 
aerobic and mycobacterial media. The colonies were 
small, rough and creamy white or slightly yellow on 
blood agar, and appeared smooth, dull and creamy white 
on Lowenstein-Jensen media after incubation at 37°C 
for 3-7 days. They are gram-variable and positive for 
acid-fast stain. The identification of. rapidly growing 
mycobacteria was based on growth on MacConkey agar 
(crystal violet free) and a positive arylsulfatase reaction 
within 3 days. M. fort&urn group was differentiated 
from M. chelonae/abscessus group on the basis of 
positive iron uptake and nitrate reduction.22 With our 
set of biochemical tests, M. chelonae was not dis- 
tinguished from M. abscessus, and M. fort&urn group 
was not differentiated from the biovar. Susceptibility 
testing was done by the disk diffusion method. A 
Mueller-Hinton agar plate was swabbed with OADC 
(oleic acid albumin dextrose catalase) on its surface.The 
organisms in Mueller-Hinton broth with a turbidity 
equivalent to 0.5 McFarland were swabbed onto the 
surface. Commercial bacterial antibiotic disks were used 
and incubated at 37°C for 3-4 days until there were 
signs of growth. The zones of inhibition were measured. 
Susceptibility or resistance to individual agents was 
recorded according to the suggested susceptibility-zone 
diameter.23 
RESULTS 
There were 22 cases infected by M. chelonae/abscessus 
group or M. fort&urn group from January 1993 to June 
1999 in Ramathibodi Hospital. Two cases were excluded 
because the files were not available. The details of 20 
cases are given in Table 1. The pathologic diagnosis of 
Table 1. Cases infected with rapidly growing mycobacteria 
the tissues or pus from infected organs is shown in Table 
2. Table 3 shows the patterns of susceptibility of various 
antimicrobial agents to the organisms. Three of 20 cases 
with different presentations and different problems are 
presented as case reports. 
Case reports 
Case 7 
A 40-year-old man was admitted due to prolonged fever 
for 6 weeks. He had been well until 6 weeks prior to 
admission, when he developed persistent low-grade 
fever. Four weeks prior to admission, he had developed 
migratory joint pain from the right big toe, to both 
ankles, both knees, both wrists, and the right index finger. 
The joint pain spontaneously disappeared 1 week prior 
to admission, but a rash on the right hand appeared 
instead. He noticed a 7-kg weight loss in these 6 weeks. 
On admission, he had a temperature of 38.5”C. 
There was lymphadenopathy in the right submandibular 
and left anterior cervical areas. The liver was enlarged. 
Erythematous maculopapular rashes were found on the 
upper chest, both hands, and both feet. Other physical 
findings were unremarkable. The results of laboratory 
investigations, including complete blood count, liver 
function test, blood urea nitrogen and creatinine, anti- 
nuclear antibody, rheumatoid factor, venereal disease 
research laboratory (VDRL), chest radiograph, and ultra- 
sound of abdomen, were within normal ranges. Anti- 
HIV antibody was negative, and three hemoculture 
specimens were negative. 
Cervical lymph node biopsy was performed, and the 
imprint stain showed rare acid-fast bacilli. The patho- 
logic diagnosis of the node was chronic and acute 
lymphadenitis with poorly formed granuloma. Skin 
lesion biopsy was done, and the pathologic diagnosis was 
Sweet’s syndrome. The patient was primarily treated as 
for tuberculosis, with isoniazid, rifampicin, ethambutol, 
and pyrazinamide. After 1 week of treatment, the patient 
still had fever and no improvement. 
Case Age, Diagnosis Organism 
gender 
Underlying Treatment Outcome 
diseases 
1 57, M lntraabdominal M. fort&urn None Good, but lost 
lymphadenitis, 
Clarithromycin + 
group doxycycline + to follow-up 
anemia gentamicin after 7 weeks’ 
treatment 
2 39, F Bilateral cervical M. chelonael None 
lymphadenitis, 
Clarithromycin + Good, but relapse 
a bscessus amikacin + 6 months after 
left parotitis, group imipenem 
anemia, 
stopping treatment 
(doxycycline)” 
Sweet’s syndrome 
3 32, F Right supraclavicular M. chelonael None Good, but 
lymphadenitis, 
Clarithromycin + 
abscessus amikacin relapsed after 
group (doxycycline)” stopping treatment 
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Table 1. (Continued) 
Case Age, 
qender 
Diagnosis Organism Underlying 
diseases 
Treatment Outcome 
4 59, F Right cervical 
lymphadenitis, 
anemia 
5 47, F Bilateral cervical 
lymphadenitis, 
multiple bone 
infection, 
right parotitis, 
anemia, 
Sweet’s syndrome 
6 52, F Cervical 
lymphadenitis, 
anemia, 
Sweet’s syndrome 
7 40, M Cervical and 
inguinal 
Ivmohadenitis, 
iweet’s syndrome, 
psoriasis 
8 24, F Neck abscess 
9 27, F Breast abscess 
10 40, F Chronic subcutaneous 
nodule 
11 18, F Nodule on tattoo 
12 27, F Chronic skin 
ulcers & subcutaneous 
abscess 
13 52, F Skin plaque 
14 34, M Genital M. fortuitum 
inguinal abscess group 
15 38, M Pulmonary M. chelonael 
infection abscessus group 
16 41, F Right COM, 
right mastoiditis, 
sigmoid sinus thrombosis 
17 44, M Right cornea1 ulcer 
18 39, M Left cornea1 ulcer 
19 
20 
66, F Left cornea1 ulcer, M. chelonael 
endophthalmitis abscessus group 
24, F Endophthalmitis 
M. chelonael Rheumatoid 
abscessus group arthritis 
M. chelonael 
abscessus group 
None 
M. chelonael 
abscessus group 
M. chelonael 
abscessus group 
M. chelonael 
abscessus group 
M. chelonael 
abscessus group 
M. chelonael 
abscessus group 
M. chelonael 
abscessus group 
M. chelonael 
abscessus group 
M. chelonael 
abscessus group 
M. chelonael 
abscessus group 
M. fortuitum 
group 
M. chelonael 
abscessus group 
M. chelonael 
abscessus group 
Clarithromycin + 
netilmicin 
(fusidic acid)” 
Clarithromycin + 
amikacin 
(netilmicin)a 
None Clarithromycin + 
amikacin + 
ciprofloxacin + 
(cotrimoxazole)a 
None Clarithromycin + 
amikacin 
None Drainage 
None Drainage 
None Clarithromycin + 
amikacin 
None Excision 
Cotrimoxazole 
SLE Clarithromycin + 
amikacin + 
cotrimoxazole + 
doxycycline 
None Clarithromycin 
Ciprofloxacin 
HIV positive 
HIV positive 
Previous 
pulmonary TB 
None 
Clarithromycin + 
amikacin + 
cotrimoxazole + 
ofloxacin 
Clarithromycin + 
amikacin + 
imipenem 
None Cotrimoxazole 
Rifamuicin 
Cefazblin ED 
Gentamicin ED 
None Clarithromycin 
Fusidic acid 
Amikacin ED 
Hypertension Tetracycline 
Cefazolin ED 
Gentamicin ED 
None Enucleation 
Choramphenicol ED 
Good, no relapse 
4 months after 
stopping treatment 
Poor, 
needed surgery, 
relapse 3 weeks 
after stopping 
treatment 
Good, no relapse 
7 months after 
stopping treatment 
Poor, needed surgery, 
breakthrough 
on medication 
Lost to follow-up 
before treatment 
Lost to follow-up 
before treatment 
Good, 
needed surgery 
Good, no relapse 
15 months after 
stopping treatment 
Good, 
breakthrough 
on medication, 
needed surgery 
Good, 
no relapse 2 years 
after stopping 
treatment 
Good, 
no relapse 6 months 
after stopping 
treatment 
Died before 
treatment 
Poor, breakthrough 
on medication, 
needed multiple 
operations 
Good 
Good 
Good 
Good 
ED, eyedrop; SLE, systemic lupus erythematosus; COM, chronic otitis media. 
=Short course of treatment. 
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Table 2. Pathologic findings of the tissue from infected organs 
Infected organ and 
pathological diagnosis 
AFB Number 
(specimens) 
1. Lymph node 
Nonspecific lymphadenitis 
Acute / chronic inflammation 
Acute and chronic lymphadenitis 
with focal fibrosis 
Acute suppurative lymphadenitis 
Suppurative granuloma with 
eosinophilia 
Suppurative granuloma with 
caseous necrosis 
Caseous granuloma 
Granulomatous lymphadenitis 
Non-caseating granulomatous 
lymphadenitis 
Mixed lymphoid cells with 
vascular proliferation 
2. Tonsils 
Pleomorphic reticulosis 
3. Bone 
Necrotic tissue with acute 
inflammation 
Acute inflammation with 
multinucleated giant cells 
4. Skin and soft tissue 
Chronic inflammation 
Chronic eczema with excoriation 
Suppurative granulomatous 
inflammation 
Suppurative and focal 
granulomatous inflammation 
Necrotizing granulomatous 
inflammation 
5. Mastoid and middle ear 
Chronic inflammation with 
epitheloid granuloma 
Granulomatous inflammation 
with caseous necrosis 
Cholesteatoma 
6. Pus from abscess 
7. Sputum 
- 1 
- 2 
+ 2 
+ 1 
+ 1 
- 1 
- 1 
- 2 
- 1 
- 1 
+ 1 
- 1 
- 1 
- 1 
+ 1 
- 2 
+ 1 
- 1 
- 2 
- 1 
- 1 
+ 314 
+ 212 
Mycobacterial culture of the node on the seventh 
day revealed growth of colonies with positive acid-fast 
bacilli, and rapidly growing mycobacteria were 
considered. Treatment was then switched to oral 
clarithromycin 500 mg twice daily and intravenous 
amikacin 500 mg once daily. The organism was identified 
on the 14th day as M. chelonae/abscessus, and was 
susceptible to gentamicin, netilmicin, amikacin, tobra- 
mycin, and erythromycin, and resistant to cefoxitin, 
imipenem, meropenem, ofloxacin, ciprofloxacin, cotri- 
moxazole, and tetracycline. The right submandibular and 
left anterior cervical lymph nodes were not palpable 
after 2 months of treatment. The patient was discharged 
on clarithromycin, and continued to be given intra- 
venous amikacin in the outpatient clinic. 
Although the patient showed good adherence to the 
medication, he had two episodes of breakthrough 
lymphadenitis and two individual episodes of dermato- 
logic disease in a period of 6 months. The first episodes 
of breakthrough lymphadenitis occurred when he had 
been receiving clarithromycin and amikacin for 4 months. 
The manifestations were acute fever, matted nodes at 
the right groin, and a right upper thigh abscess. Culture 
of the pus from the right thigh abscess grew M. chelonae/ 
abscessus group, and the the results of susceptibility 
testing were similar to those of the first strain. The 
abscess was drained, and the right inguinal lymph nodes 
were excised. The pathologic diagnosis was necrotizing 
granulomatous inflammation. Treatment was switched 
to oral azithromycin 750 mg, oral sparfloxacin 200 mg, 
and intravenous netilmicin 300 mg once daily. 
The second episode of breakthrough lymphadenitis 
occurred when the patient had taken azithromycin, 
sparfloxacin and netilmicin for 4 weeks and presented 
with acute fever and bilateral cervical lymphadenopathy. 
Right radical neck dissection with left-modified radical 
neck dissection was performed. The node culture grew 
the same organism, with the same susceptibility. Suscept- 
ibility testing for trovafloxacin was done, and showed the 
organism to be resistant to this agent. Azithromycin, 
imipenem and amikacin were given. In both episodes, the 
patient improved with combined medical and surgical 
treatment. The intention was for him to take long-term, 
unlimited medication. However, a new relapse is possible, 
and he might need further surgical resection. 
The two individual episodes of dermatologic disease 
in this patient were psoriasis and Sweet’s syndrome. 
Both episodes occurred few weeks before the episodes 
of breakthrough lymphadenitis, and were confirmed 
by biopsy. The organism was not found in cultures of 
the blood and skin lesions. Psoriasis was improved with 
etretinate and topical mineral oil, and Sweet’s syndrome 
subsided after a short course of prednisolone. 
Case 12 
A 27-year-old woman presented with a history of chronic 
ulcers on the right leg for 3 months. She had no 
underlying disease. Three months prior to admission, she 
had developed an ulcer with pus on the pretibial area 
of the right leg. The ulcer then enlarged, and became 
surrounded by multiple small ulcers. The patient had no 
fever or other symptoms. She went to see a doctor, and 
a skin biopsy was done. Acid-fast bacilli were found 
in acid-fast stain of the pus, and skin biopsy showed 
mixed acute suppurative inflammation and focal 
granulomatous inflammation within the deep dermis and 
subcutaneous fat. Tuberculosis of the skin was diagnosed, 
and antituberculous drugs were given. The skin lesions 
did not improve after 2 months of medication, and the 
patient was transferred to Ramathibodi Hospital. 
The patient had underlying disease, diagnosed as 
systemic lupus erythematosus with renal involvement, 
and was on oral prednisolone 15 mg daily. She could not 
recall any previous injury to the right leg. 
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Table 3. Susceptibility patterns of rapidly growing mycobacteria to antibiotics 
Antibiotics M. chelonaelabscessus group M. fortuitum group 
All tested Resistant Susceptible All tested Resistant Susceptible 
(strains) (strains) (strains) (%) (strains) (strains) (strains) f%) 
Penicillin 13 13 0 0 2 2 0 0 
Cefoxitin 13 13 0 0 1 0 1 100 
lmipenem 10 3 7 70.0 1 0 1 100 
Gentamicin 13 6 7 53.8 3 0 3 100 
Amikacin 13 0 13 100 3 0 3 100 
Netilmicin 13 0 13 100 3 0 3 100 
Tobramycin 13 0 13 100 3 0 3 100 
Ofloxacin 13 13 0 0 2 0 2 100 
Ciprofloxacin 11 10 1 9.1 1 0 1 100 
Lincomycin 11 10 1 9.1 3 3 0 0 
Erythromycin 13 8 5 38.5 3 3 0 0 
Chloramphenicol 4 4 0 0 2 1 1 50 
Cotrimoxazole 13 11 2 15.4 3 0 3 100 
Tetracycline 10 10 0 0 2 0 2 100 
Fosfomycin 7 7 0 0 2 2 0 0 
Vancomycin 12 11 1 8.3 1 0 1 100 
Teicoplanin 6 5 1 16.7 1 1 0 0 
Fusidic acid 9 7 2 22.2 2 1 1 50 
On admission, the patient had a cushingoid 
appearance. There was a dirty wound with exudate, 
2 x 2 cm in diameter, surrounded by multiple small 
ulcers, crust, and erythematous papules, on the right 
leg. Acid-fast stain of the pus from the large ulcer 
showed numerous acid-fast bacilli. Culture revealed 
M. chelonae/abscessus group, which was susceptible to 
gentamicin, netilmicin, tobramycin, and amikacin, and 
resistant to cefoxitin, imipenem, meropenem, ofloxacin, 
ciprofloxacin, erythromycin, cotrimoxazole, and tetra- 
cycline. Clarithromycin 500 mg twice daily and amikacin 
750 mg once daily were given. The skin lesions improved 
within 3 weeks, and treatment was discontinued. 
Four weeks after discontinuation of treatment, the 
patient had relapse of an ulcer on the pretibial area of 
the right leg, and pustular eruptions on the right thigh. 
The organism was not found with acid-fast stain and 
culture. Clarithromycin and amikacin were given. An 
operation for wide excision of the ulcer and subsequent 
skin graft was performed. The pathologic diagnosis of 
the ulcer was necrotizing granulomatous inflammation. 
The pustular eruptions subsided after 3 weeks of 
medication, and the surgical wound healed. The 
medication was continued for 8 weeks. The patient was 
discharged, and was followed up for 8 months at the 
outpatient clinic without any relapse. 
Case 16 
A 41-year-old woman presented with progressive 
headache, a painful right eye, and a painful right ear. She 
had a 3-year history of chronic otitis media of the right 
ear and multiple operations for tympanoplasty. She was 
admitted with the diagnosis of right chronic otitis media 
and sclerosing mastoiditis. A right radical mastoid- 
ectomy was performed. The pathologic diagnosis was 
chronic inflammation with focal tissue necrosis. After 
the operation, the patient’s headache persisted, and she 
developed tinnitus in the right ear. Examination of the 
right ear showed whitish granulation tissue in the 
middle ear and mastoid cavity. The results of neurologic 
examination were normal. MRI of the brain and temporal 
bone showed a mixed enhancing soft tissue mass at 
the right petrous ridge, cerebropontine angle cisterns, 
tentorium, right sigmoid sinus, right middle ear cavity, 
and mastoid air cells, compatible with a chronic 
infectious process. Biopsy of the granulation tissue in the 
right middle ear and mastoid cavity was performed. The 
pathologic diagnosis of the granulation tissue was 
granulomatous inflammation with caseous necrosis. 
Acid-fast stain was negative. Tissue culture grew M. 
chelonae/abscessus group, which was susceptible to 
imipenem, netilmicin, amikacin, and erythromycin, and 
resistant to cefoxitin, ofloxacin, ciprofloxacin, cotrimoxa- 
zole, and tetracycline. Oral clarithromycin 500 mg twice 
daily, intravenous imipenem 500 mg every 6 h and 
amikacin 750 mg once daily were given. 
After 8 weeks of treatment, the patient’s symptoms 
had slightly improved, but follow-up MRI of the 
temporal bone gave the same results as the first MRI. A 
right radical mastoidectomy was performed. The patho- 
logic diagnosis of the right mastoid mucosa was 
cholesteatoma, and no organism was found with the 
special stain. Treatment was continued throughout the 
4-month hospitalization period. The third MRI of the 
temporal bone showed moderate reduction of the 
enhancing lesion in the rest of the right mastoid air cell 
and middle ear cavity. The patient was discharged on 
clarithromycin and alternate-day amikacin. Her clinical 
status was stable. 
The patient was admitted on two more occasions, 
with acute attacks of headache and right ear pain. 
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Multiple operations for the revision of the right 
mastoidectomy were performed before improvement 
was seen. There was no growth of organisms in tissue 
culture for mycobactera in three individual episodes. 
The patient had sigmoid sinus thrombosis as a complic- 
ation of disease on one admission. Oral clarithromycin 
and cotrimoxazole, and amikacin eardrops, were given 
concurrently and continued for 18 months without 
clinical relapse. 
DISCUSSION 
Rapidly growing infections with mycobacteria in humans 
are primarily caused by M. chelonae/abscessus group 
and M. fortuitum group. Both groups grow on routine 
bacteriologic media, as well as on mycobacterial media, 
in 7 days or less.24 The organisms are increasingly 
recognized as pathogens, and the clinical syndrome is 
variable. According to the organ infected, the cases in 
our study could be divided into five groups. The first 
group had lymphadenitis, and consisted of the first seven 
cases. The second group had skin and soft tissue 
infections, and consisted of cases 8-14.The 15th case was 
in the third group, pulmonary infection, and the 16th 
case was in the fourth group, ear infection. The fifth 
group, eye infection, consisted of the last four cases. The 
fifth and seventh cases were considered to have 
disseminated infection, because of simultaneous multiple 
bone infections and multiple areas of lymphadenitis, 
respectively. 
Among 20 cases, only four were considered to 
be immunocompromised hosts, consisting of two cases 
with HIV infection, one case with systemic lupus 
erythematosus on steroid therapy, and one case with 
rheumatoid arthritis on steroid therapy. The higher 
proportion of immunocompetent patients in our study 
than in the previous study20 suggests that infections with 
rapidly growing mycobacteria could occur in apparently 
normal hosts. The incidence of M. chelonae/abscessus 
group infection was higher than that of M. fortuitum 
group infection in our study, consistent with the results 
of previous studies.10J1,20 
Seven of the 20 patients in our study presented with 
lymphadenitis. The number was higher than that in a 
recent review, which identified 54 cases of infections 
with rapidly growing mycobacteria since 1960, only 
three of which resulted in lymphadenitis?O The nodes 
involved in these patients were the cervical, supra- 
clavicular or intra-abdominal lymph nodes. The patho- 
logy of the various tissues was nonspecific and not 
diagnostic. Even though some specimens showed 
positive acid-fast bacilli, they could not be differentiated 
from tuberculosis, the more common disease. Culture 
for mycobacteria was more specific and helpful. Four of 
seven cases had associated Sweet’s syndrome that was 
supported by clinical and histologic evidence. All of 
them were infected with M. chelonae/abscessus group. 
This finding supports the findings of previous studies25,26 
that reported Sweet’s syndrome associated with M. 
chelonae/abscessus group infection. We observed that 
three of our four cases with Sweet’s syndrome had 
recurrence when there were clinical relapses of lymph- 
adenitis. Our observations and previous data indicate 
that awareness of infections with rapidly growing 
mycobacteria is necessary when patients present with 
lymphadenitis and Sweet’s syndrome. 
The seven cases presenting with skin and soft tissue 
infections in our study comprised skin and subcutaneous 
infections, nodules on tattoo, neck, and breast, and 
inguinal abscesses. The fact that 41 of 54 patients pre- 
sented with this entity in an earlier review20 is evidence 
that skin and soft tissues are common sites of infection. 
Acid-fast stain is helpful for recognition of myco- 
bacterial infection. This finding indicates the desirability 
of doing acid-fast stain in tissue and, particularly, pus 
from the abscess to achieve rapid diagnosis of myco- 
bacterial infection. 
The case of pulmonary infection in our study was a 
patient with advanced symptomatic HIV Because the 
patient had been previously treated for pulmonary 
tuberculosis and concurrent cryptococcal meningitis, 
which was the cause of death, the diagnosis of M. 
chelonae/abscessus group pulmonary infection could not 
definitely be made by the diagnostic criteria of The 
American Thoracic Society.21 However, we proposed 
that pulmonary infection was present, as this patient was 
a possible case of infection with rapidly growing 
mycobacteria, especially given the immunocompro- 
mised condition. 
The case of otitis media and mastoiditis in our study 
was chronic and did not respond to many conventional 
antibiotics. The diagnosis was made after mycobacterial 
infection was detected. The patient had multiple 
episodes of recurrence despite surgical resection and 
appropriate medical treatment. This might be another 
site of infection with rapidly growing mycobacteria that 
was difficult to treat. The previous study including 21 
patients with chronic otitis media caused by rapidly 
growing mycobacteria had documented that treatment 
for this entity is difficult, requiring debridement and 
prolonged antibiotic therapy.27 This study also proposed 
that tympanostomy tube placement is a risk factor for 
this infection. 
Three of four cases of eye infection in our study 
reported previous eye injury, consistent with a previous 
study of 22 patients, in which 91% had previous eye 
injury.‘l The 20th case, who had endophthalmitis and 
needed surgery for nucleation, had a history of 
penetrating eye injury 3 years prior to the infection. Eye 
surgery is another risk factor for endophthalmitis, 
according to previous reports.28,29 
Treatment of infections with rapidly growing 
mycobacteria is difficult, because of resistance to con- 
ventional antituberculous drugs and many antibiotics, 
and common clinical relapse. The seventh and sixteenth 
cases in our study as presented above demonstrate the 
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difficulty of treatment. Although a prior study suggested 
that primary treatment should be local excision of the 
affected lymph nodes5 many studies have reported the 
success of medical treatment with and without surgical 
treatment.2-4,6-20 Seventeen cases in our study had 
received the treatment, and 13 of these had good clinical 
outcome.The other two cases with fair clinical outcomes 
and two cases with poor clinical outcomes needed 
concurrent surgical treatment. 
The antimicrobial susceptibilities of M. chelonae/ 
abscessus group and M. fort&urn group were 
different.30 All strains of M. fort&urn are susceptible to 
cotrimoxazole,30 ciprofloxacin, and ofloxacin,31 and 
some strains are susceptible to cefoxitin, doxycycline, 
and erythromycin,30 whereas fewer than 20% of M. 
chelonae/abscessus group are susceptible to these 
drugs.30,32-34 The susceptibility patterns of these drugs 
found in our study are similar to these. 
A study in 1978 suggested that amikacin is a 
promising drug for the treatment of both M. chelonae 
and M. fortuitum infection,35 and a study by Swenson 
has confirmed this. According to the results of our study, 
all strains of M. chelonae/abscessus group and M. 
fortuitum group are susceptible to amikacin and 
netilmicin. Clarithromycin is another drug that actively 
inhibits both groups of organisms, and is lo-50 times 
more potent than erythromycin against M. chelonae/ 
abscessus group. Unfortunately, before 1999 we had not 
tested the susceptibility of the organisms to clarithro- 
mycin in clinical practice, because disks were unavail- 
able. However, a previous study that enrolled some 
patients from our study3’j showed that 91.7% of M. 
chelonae/abscessus group strains and 71.4% of M. 
fortuitum group strains were susceptible to clarithro- 
mycin by E-test MIC study. The other 28.6% of M. 
fortuitum group were intermediately resistant to 
clarithromycin. Imipenem was the only B-lactam active 
against M. chelonae/abscessus group for 39% of strains 
in a previous study. 32 Seventy per cent of the cases 
infected by M. chelonae/abscessus group in our study 
were susceptible to imipenem. Because of the variations 
in susceptibility by and within species subgroups, 
we recommend susceptibility testing if the test is 
available. 
Clinical therapeutic trials of infections with rapidly 
growing mycobacteria are scanty. A clinical trial of 
clarithromycin for cutaneous infection due to M. 
chelonae suggests that clarithromycin may be the drug 
of choice.37 However, the later reports of rapid 
development of resistance to clarithromycin mono- 
therapy for M, chelonae infection3* and quinolone 
monotherapy for M. fortuitum infection33 suggest that 
combination therapy is more suitable. Medical 
treatment of the patients in our study included two- or 
three-drug combinations. The outcome of treatment 
varied among each group of diseases. Most of the 
patients with lymphadenitis had good clinical outcome. 
The cases with fair and poor clinical outcomes had more 
involved lymph nodes at first presentation, and they 
needed surgical resection. This suggests that widespread 
lymph node involvement may be a poor prognostic sign. 
Relapse was common in this group, especially in the 
cases with multiple node involvement. We recommend 
using at least three drugs to which the organism is 
susceptible for medical therapy, and continuing treat- 
ment long term. Surgical resection, if possible, is helpful 
for the patient with lymphadenitis. 
The patients with cutaneous infection responded 
well to the treatment, but the extensive skin lesion also 
needed surgery. If an abscess was present, drainage was 
indicated. Successful topical amikacin monotherapy for 
keratitis was reported in one study, but 75% of patients 
needed early keratectomy.ll We still recommend using at 
least two or three topical and systemic drugs for medical 
therapy. Cases with endophthalmitis may need surgery to 
control the disease. Since a previous study reported that 
more patients on concurrent corticosteroid therapy had 
failed medical therapy,lO we recommend the avoidance 
of corticosteroid therapy in these patients. 
CONCLUSIONS 
Infections with rapidly growing mycobacteria present 
with variable clinical syndromes. The diseases can occur 
in apparently normal hosts. Awareness of the organism 
can lead to diagnosis and suitable treatment. Culture of 
mycobacteria from clinical specimens is necessary for 
definitive diagnosis, since the pathology is nonspecific. In 
our study, clinical responses varied. Relapse was 
common, particularly in the cases with lymphadenitis. 
Medical therapy, including two or three drugs to which 
the organism is susceptible, is recommended. Surgical 
resection is indicated in cases with failed medical 
therapy and/or clinical relapse. 
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